Filing Details
- Accession Number:
- 0001209191-15-083423
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-12-03 21:05:29
- Reporting Period:
- 2015-12-01
- Filing Date:
- 2015-12-03
- Accepted Time:
- 2015-12-03 21:05:29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1190290 | Elaine Ullian | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2015-12-01 | 22,500 | $59.55 | 27,765 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2015-12-01 | 6,289 | $128.78 | 21,476 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-12-01 | 10,711 | $129.77 | 10,765 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-12-01 | 5,400 | $130.68 | 5,365 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-12-01 | 100 | $131.38 | 5,265 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2015-12-01 | 22,500 | $0.00 | 22,500 | $59.55 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2022-05-31 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $128.78 (range $128.25 to $129.23).
- Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $129.77 (range $129.25 to $130.24).
- Open market sales reported on this line occurred at a weighted average price of $130.68 (range $130.26 to $131.25).
- Fully vested.
Billionaire Hedge Funds
